MX2023008810A - Proceso de preparacion de mavacamten y formas en estado solido del mismo. - Google Patents

Proceso de preparacion de mavacamten y formas en estado solido del mismo.

Info

Publication number
MX2023008810A
MX2023008810A MX2023008810A MX2023008810A MX2023008810A MX 2023008810 A MX2023008810 A MX 2023008810A MX 2023008810 A MX2023008810 A MX 2023008810A MX 2023008810 A MX2023008810 A MX 2023008810A MX 2023008810 A MX2023008810 A MX 2023008810A
Authority
MX
Mexico
Prior art keywords
mavacamten
preparation
solid state
state forms
present application
Prior art date
Application number
MX2023008810A
Other languages
English (en)
Inventor
Sharmistha Pal
Divya Jyothi Kallem
Srinivas Oruganti
Magesh Sampath
Kottur Mohan Kumar
Saikat Sen
Arijit Mukherjee
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of MX2023008810A publication Critical patent/MX2023008810A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente solicitud se refiere al proceso para la preparación de Mavacamten, métodos preparativos de varias formas cristalinas de Mavacamten y forma amorfa de Mavacamten, su método preparativo, y composiciones farmacéuticas de los mismos. La presente solicitud también se refiere a las dispersiones sólidas de Mavacamten, sus métodos preparativos y composiciones farmacéuticas que contienen dispersiones sólidas de Mavacamten.
MX2023008810A 2021-02-01 2022-01-31 Proceso de preparacion de mavacamten y formas en estado solido del mismo. MX2023008810A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202141004381 2021-02-01
IN202141006543 2021-02-16
IN202141021624 2021-05-13
IN202141045274 2021-10-05
PCT/IN2022/050080 WO2022162701A1 (en) 2021-02-01 2022-01-31 Process for preparation of mavacamten and solid state forms thereof

Publications (1)

Publication Number Publication Date
MX2023008810A true MX2023008810A (es) 2023-08-04

Family

ID=82652691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008810A MX2023008810A (es) 2021-02-01 2022-01-31 Proceso de preparacion de mavacamten y formas en estado solido del mismo.

Country Status (4)

Country Link
US (1) US20240082248A1 (es)
CA (1) CA3206864A1 (es)
MX (1) MX2023008810A (es)
WO (1) WO2022162701A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230144117A (ko) * 2013-06-21 2023-10-13 미요카디아, 인크. 심장 상태에 대한 피리미딘디온 화합물
CA3071948A1 (en) * 2017-08-04 2019-02-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Also Published As

Publication number Publication date
WO2022162701A1 (en) 2022-08-04
US20240082248A1 (en) 2024-03-14
CA3206864A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
MX2023004157A (es) Composiciones de oligosacaridos para el uso como alimento para animales y sus metodos para producirlas.
MX2021013812A (es) Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a ]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil) pirrolidin-1-carboxamida y formas en estado solido de la misma.
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
WO2018237037A3 (en) HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
MX2019015744A (es) Composiciones farmaceuticas.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
WO2017177004A8 (en) Tertiary amides and method of use
EP4327880A3 (en) Solid state form of ribociclib succinate
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
WO2019224790A3 (en) Prodrugs of fulvestrant
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
WO2018069941A3 (en) Polymorphic forms of venetoclax
MX2022007999A (es) Streptococcus thermophilus negativo a sacarosa para su uso en la preparación de productos fermentados.
MX2016000968A (es) Composiciones edulcorantes estables.
MX2021003358A (es) Polisacaridos capsulares purificados de streptococcus pneumoniae.
MX2023008810A (es) Proceso de preparacion de mavacamten y formas en estado solido del mismo.
AU2014324961A8 (en) Highly potent glucocorticoids
WO2019027173A3 (ko) 신규한 싸이코스-6-인산 탈인산효소, 상기 효소를 포함하는 사이코스 생산용 조성물, 상기 효소를 이용하여 사이코스를 제조하는 방법
PH12019502462A1 (en) Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
WO2018193090A3 (en) METHOD FOR PREPARING ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2021006808A (es) Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma.
MX2020013857A (es) Bacterias bifidobacterium bifidum no viables y usos de las mismas.